A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults

A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals

NCT05472038 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

NCT05293665 ·Status: UNKNOWN ·Phase: PHASE3

Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity

NCT05076227 ·Status: COMPLETED

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

NCT07069309 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

NCT06354998 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity After COVID-19 Vaccines in Adapted Schedules

NCT06189040 ·Status: COMPLETED ·Phase: PHASE4

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

NCT04762680 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2

NCT04907331 ·Status: UNKNOWN ·Phase: PHASE2

Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19

NCT04844268 ·Status: UNKNOWN ·Phase: PHASE1

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

NCT05815498 ·Status: COMPLETED ·Phase: PHASE3

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

NCT05463068 ·Status: COMPLETED ·Phase: PHASE3

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

NCT04368988 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

COVID-19 Booster Study in Healthy Adults in Australia

NCT05658523 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults

NCT05029856 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized

NCT05016934 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

NCT00397943 ·Status: COMPLETED ·Phase: PHASE2

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

NCT00914732 ·Status: COMPLETED ·Phase: PHASE2

Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine

NCT05354024 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

NCT04611802 ·Status: COMPLETED ·Phase: PHASE3

Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine

NCT05040789 ·Status: WITHDRAWN ·Phase: PHASE3

A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines

NCT05933512 ·Status: UNKNOWN ·Phase: PHASE2

Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions

NCT04961502 ·Status: UNKNOWN ·Phase: NA

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines

NCT05372588 ·Status: COMPLETED ·Phase: PHASE3

Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

NCT01263691 ·Status: COMPLETED ·Phase: PHASE1